Fisetin Bioavailability: The Flavonoid Absorption Problem

Unformulated oral fisetin produced low circulating parent-fisetin concentrations in a small human crossover study. A hybrid-hydrogel formulation produced substantially higher measured exposure, but neither result establishes a clinical dose or a human concentration required for senolytic activity [1]. This distinction matters when interpreting supplement claims. For dose research, see our dosage review.

What does the Krishnakumar 2022 study tell us about fisetin absorption?

This randomised, double-blind crossover trial involved 15 healthy volunteers. In separate periods, participants received 1,000 mg unformulated fisetin or 1,000 mg of the FF-20 hybrid-hydrogel product containing approximately 192 mg fisetin. Each dose was given after at least 10 hours of fasting, followed by standardised meals beginning one hour later. Blood sampling included 0.5, 1, 2, 3, 5, 8 and 12 hours after administration [1].

The paper adjusted reported pharmacokinetic results to account for the approximately fivefold difference in actual fisetin content between products. Its dose-adjusted parent-fisetin Cmax was 9.97 ng/mL for the unformulated comparator and 238.2 ng/mL for FF-20, a 23.9-fold difference; dose-adjusted 12-hour AUC differed by 26.9-fold [1]. Do not mistake 9.97 ng/mL for the unadjusted observed peak after the complete approximately 982 mg unformulated dose. These data describe a specific product, single-dose conditions and 15 healthy adults; they do not establish an optimal regimen or any clinical benefit.

Fisetin pharmacokinetics: the correctly adjusted numbers

Study measurement	Unformulated fisetin	FF-20 hybrid hydrogel
Product mass administered	1,000 mg (98.2% fisetin)	1,000 mg formulation (19.2% fisetin)
Actual fisetin contained	Approximately 982 mg	192 mg
Dose-adjusted Cmax	9.97 ng/mL	238.2 ng/mL (23.9×)
Dose-adjusted 12-hour AUC	12.67 ng·h/mL	341.4 ng·h/mL (26.9×)
Participants / conditions	15 healthy adults; randomized crossover; overnight fasting with food provided later; single-dose pharmacokinetics

Do not interpret these as the two unadjusted observed plasma peaks. The authors adjusted the PK comparison for unequal fisetin content. Higher circulating exposure with this particular formulation does not establish a senolytic concentration threshold or clinical superiority [1].

Study funding and the difference between trial and retail doses

The 2022 trial was financially supported by Akay Natural Ingredients, which patented the tested Hybrid-FENUMAT technology. Four authors were affiliated with Akay, and two were affiliated with Life Extension, which markets FF-20 as Bio-Fisetin [1]. This does not negate the measured pharmacokinetic difference, but independent replication and transparent commercial disclosure are important when interpreting it.

Do not equate the trial dose with the retail capsule: the investigated FF-20 serving provided approximately 192 mg of actual fisetin, whereas Life Extension's current Bio-Fisetin label lists 8 mg fisetin per capsule. The study was not a pharmacokinetic trial of a single 8 mg retail capsule; its reported plasma values cannot be assumed to occur at that label dose without human dose-proportionality data. Neither studied exposure establishes clinical senolysis or a longevity benefit.

Why is fisetin absorbed so poorly?

1. Low aqueous solubility

Fisetin dissolves poorly in water, a plausible limitation on delivery from ordinary oral products. Laboratory solubility measurements and dissolution models can help explain the challenge, but the 2022 human trial did not determine an absolute absorption ceiling or whether exposure increases linearly across larger doses.

2. Metabolism and conjugation

Fisetin can be converted to geraldol and conjugated metabolites such as glucuronides and sulfates. These pathways have been described mainly in experimental studies [2] [3]. The contribution of each pathway to total exposure and clinical effects after different oral doses in humans remains incompletely characterised.

3. Elimination and distribution

The published human single-dose study tracked parent fisetin and geraldol over 12 hours, but it was not designed to quantify all routes of elimination, long-term accumulation or organ-specific tissue concentrations. Claims that human fisetin is cleared mainly through bile, or that any daily dose cannot accumulate, would require additional human data.

These limitations explain why formulation research is relevant. They do not establish a safe maximum self-administered dose or a validated way to overcome low exposure.

Why does fisetin's metabolite, geraldol, matter?

Geraldol is a methylated fisetin metabolite measured alongside parent fisetin in human plasma [1]. Some cell experiments have identified biological activity for geraldol, but activity against a tumour cell line does not establish that it clears senescent human cells [2].

It is therefore misleading to compare a single parent-fisetin blood concentration directly with a cell-culture senolytic concentration and declare a human treatment threshold. Human tissue concentrations, unbound exposure, active metabolites and the time course of the response have not been sufficiently characterised [4].

Which fisetin formulations actually improve absorption?

Several formulation approaches try to break through this ceiling, each targeting one or more of the three limiting factors above.

Hydrogel encapsulation (FF-20)

The formulation used in the Krishnakumar study combines fisetin with galactomannan, a soluble fibre from fenugreek, and a small amount of oil [1]. The hydrogel improves how well fisetin disperses in water and may shield some of it from first-pass breakdown. Its 23-fold Cmax improvement is the largest yet published in a human fisetin pharmacokinetic study.

Liposomal formulations

Liposomal products aim to alter fisetin delivery, but a marketing label does not demonstrate improved absorption. A 2025 cell-culture experiment found that both free and liposome-encapsulated fisetin reduced IL-6 and IL-8 release from two senescent lung cell lines; neither selectively killed senescent cells in that model [5]. This does not prove a universal change in fisetin's mechanism or establish comparative human efficacy. See our liposomal fisetin review.

Nanoemulsion and nanoparticle formulations

In mice, a fisetin nanoemulsion improved bioavailability four- to 24-fold over plain fisetin [6]. A separate polymer nanoparticle formulation using a cyclodextrin inclusion complex showed similar gains in oral bioavailability, alongside stronger anticancer activity in breast cancer cells [7]. Neither approach has yet been tested in a published human trial.

Piperine co-formulation

Piperine can alter the metabolism of some compounds and medicines, but controlled human data have not established whether it improves fisetin exposure or outcomes. Its potential to affect drug metabolism is a reason not to add a concentrated piperine supplement solely on the assumption that it will enhance fisetin.

Taking fisetin with dietary fat

Fisetin's low water solubility makes a food effect plausible. However, the 2022 human study administered both formulations after an overnight fast, so it cannot demonstrate that 10–15 g of dietary fat, a specific food or a high-fat meal increases fisetin absorption. FISEKIN-1 is designed to investigate fed-versus-fasted pharmacokinetics [10]. See our administration guide.

Does a higher dose overcome limited absorption?

We do not have a reliable human dose–exposure curve for unformulated fisetin over a wide dose range. It would be scientifically unsound to extrapolate the single 1,000 mg pharmacokinetic result to predict plasma concentrations from 2,000 mg or 5,000 mg, especially when solubility and metabolism may be dose dependent.

Similarly, the intermittent schedules used in some research are experimental dosing choices, not evidence that two days of treatment achieve a useful tissue concentration or improve clinical outcomes. See our pulse-dosing evidence review for the protocols actually studied.

What does this mean for how you take fisetin?

Do not treat dietary fat as a proven absorption enhancer. The 2022 study tested formulation under fasting conditions, not fatty meals. Follow product-specific instructions and consider clinician guidance, especially alongside medication.

Do not assume that all enhanced formulations are equivalent. The measured human absorption advantage belongs to the particular hybrid-hydrogel preparation studied, and greater exposure is not proof of clinical benefit.

Do not extrapolate from one dose to very high doses. Human dose proportionality, long-term safety and an effective senolytic tissue concentration are not established.

Treat intermittent regimens as research protocols. Neither pulse frequency nor dose splitting has been clinically optimised for self-directed longevity supplementation.

For the evidence across trial designs, see our clinician's guide.

What we still don't know

We lack sufficient human data on fisetin's dose proportionality, repeated-dose accumulation, tissue distribution, active-metabolite exposure, dietary-fat effects and interactions with absorption enhancers. Nor is it established whether Cmax, total exposure or a different pharmacodynamic measure predicts senolytic activity or meaningful health outcomes.

It remains uncertain which, if any, commercial formulation improves clinical outcomes. Preclinical neuroprotection studies cannot establish brain concentrations in people [9]. Better-controlled human studies and formulation-specific comparisons are needed.

Bottom line

Unformulated fisetin produces low systemic parent-fisetin exposure in the published human pharmacokinetic study, while a specific hybrid-hydrogel formulation substantially increased exposure [1]. What that means for clinical efficacy remains unresolved: no human plasma or tissue concentration has been validated as a senolytic threshold, and no formulation has proved that higher exposure translates into a longevity benefit.

Food effects also remain unsettled. The 2022 crossover study dosed fisetin after an overnight fast and therefore did not demonstrate that dietary fat improves absorption; FISEKIN-1 is directly comparing fed and fasted exposure. The 2026 clinical-translation review likewise emphasizes heterogeneity in dose, formulation and schedule across human studies [11]. For formulation options, see our liposomal fisetin review.